Related Experiment Video

Updated: Aug 16, 2026

Intratracheal Instillation of Stem Cells in Term Neonatal Rats
04:27

Intratracheal Instillation of Stem Cells in Term Neonatal Rats

Published on: May 4, 2020

Palivizumab in infants with gestational age < or = 28 weeks and bronchopulmonary dysplasia

S Parmigiani1, A Ubaldi, C Capuano

  • 1Dipartimento di Scienze Ginecologiche, Ostetriche e di Neonatologia Sezione di Puericultura e Medicina Neonatale, Università di Parma, Italia. steparmi@inwind.it

Acta Bio-Medica De L'Ateneo Parmense : Organo Della Societa Di Medicina E Scienze Naturali Di Parma
|September 18, 2002
PubMed

Insights

This study found that palivizumab, used for respiratory syncytial virus (RSV) prevention, showed no contraindications in premature infants with severe bronchopulmonary dysplasia (BPD). Further research is needed to confirm its efficacy in this vulnerable population.

Area of Science:

  • Neonatology
  • Pediatric Pulmonology
  • Infectious Diseases

Background:

  • Severe bronchopulmonary dysplasia (BPD) increases the risk of respiratory syncytial virus (RSV) infections in premature infants.
  • Prophylactic palivizumab is used to prevent RSV, but its safety and efficacy in infants with severe BPD requiring respiratory support at discharge are not well-established.

Purpose of the Study:

  • To evaluate the safety and preliminary efficacy of prophylactic palivizumab in infants born at or before 28 weeks' gestation with severe BPD requiring pharmacologic respiratory therapy at discharge.

Main Methods:

  • A cohort of 11 infants (gestational age ≤28 weeks) with severe BPD received prophylactic palivizumab (15 mg/kg every 4 weeks, max 5 doses).
  • These infants were compared to a control group of 8 similar infants who did not require discharge therapy and received no placebo.
  • Data were collected on side effects and RSV infection rates during the November-March period.

Main Results:

  • No significant side effects were observed in the palivizumab-treated group.
  • No infant in either the treated or control group contracted RSV during the study period.
  • Preliminary data suggest palivizumab is safe for this specific high-risk infant population.

Conclusions:

  • Palivizumab appears to be safe for prophylactic use in infants born at or before 28 weeks' gestation with severe BPD requiring pharmacologic respiratory therapy at discharge.
  • Further studies are necessary to definitively assess the efficacy of palivizumab in preventing RSV infection in this vulnerable group.

More Related Videos

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease04:21

A Minimally Invasive Method for Intratracheal Instillation of Drugs in Neonatal Rodents to Treat Lung Disease

Published on: August 4, 2021

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs08:58

Development of a Neonatal Piglet Acute Lung Injury Model Recreating the Early Environment of Preterm Infant Lungs

Published on: October 31, 2025

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Asthma-IV: Nursing Management01:30

Asthma-IV: Nursing Management

The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...